Apogee Therapeutics, Inc.
APGE
$68.50
$1.732.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 44.64% | 61.05% | 75.32% | 88.50% | 99.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.69% | 59.10% | 88.39% | 103.99% | 133.19% |
| Operating Income | -31.69% | -59.10% | -88.39% | -103.99% | -133.19% |
| Income Before Tax | -40.32% | -72.80% | -100.45% | -98.24% | -116.86% |
| Income Tax Expenses | 1,444.44% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.46% | -72.96% | -100.59% | -98.34% | -116.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.46% | -72.96% | -100.59% | -98.34% | -116.88% |
| EBIT | -31.69% | -59.10% | -88.39% | -103.99% | -133.19% |
| EBITDA | -31.15% | -100.41% | -228.43% | -532.78% | -- |
| EPS Basic | -28.81% | -58.25% | -71.70% | 35.70% | 56.00% |
| Normalized Basic EPS | -28.68% | -58.10% | -71.56% | 35.73% | 56.00% |
| EPS Diluted | -28.81% | -58.25% | -71.70% | 35.70% | 56.00% |
| Normalized Diluted EPS | -28.68% | -58.10% | -71.56% | 35.73% | 56.00% |
| Average Basic Shares Outstanding | 9.97% | 9.79% | 17.49% | 57.96% | 121.58% |
| Average Diluted Shares Outstanding | 9.97% | 9.79% | 17.49% | 57.96% | 121.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |